A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Summary

This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.

Timeline

Start

2017-03-24

Primary completion

2017-11-22

Completion

2017-12-05

Drugs

Indications